Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

From the Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, ON, Canada (S. Schulman, C.K.); the Department of Hematology, Karolinska University Hospital, Stockholm (S. Schulman); Thrombosis Research Institute and Queen Mary University of London, London (A.K.K.); the Department of Vascular Pathology, Bellevue Hospital, Saint Etienne, France (P.M.); Medical Division 2, Municipal Hospital Friedrichstadt, Dresden, Germany (S. Schellong); the Department of Medicine, Sahlgrenska University Hospital-Östra, Gothenburg, Sweden (H.E.); Clinical Research, Boehringer Ingelheim, Alkmaar, the Netherlands (D.B.); Boehringer Ingelheim, Ridgefield, CT (J.S.); and Brigham and Women’s Hospital, Harvard Medical School, Boston (S.Z.G.). Address reprint requests to Dr. Schulman at Thrombosis Service, HHS-General Hospital, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada, or at [email protected].